I'm LongbridgeAI, I can summarize articles.Eloxx Pharmaceuticals reported a widened net loss of USD 4.5 million for Q2 FY26, up 138%, driven by an 181% surge in operating expenses to USD 4.45 million, primarily due to R&D costs rising 216%. For the first half, the net loss expanded 129% to USD 8.26 million. The company holds USD 62 million in cash following a public offering that raised USD 58.3 million. Eloxx aims to initiate Phase 2b clinical trials for exaluren in Q3 2026 after receiving FDA permission.
- Eloxx Pharmaceuticals mencatat rugi bersih USD 4,5 juta pada kuartal yang berakhir 30 Juni 2026, melebar 138%. * Beban operasi naik 181% menjadi USD 4,45 juta, dipimpin R&D yang melonjak 216% menjadi USD 2,84 juta. * Untuk semester I, rugi bersih melebar 129% menjadi USD 8,26 juta, sementara kas yang digunakan untuk operasi mencapai USD 10,24 juta. * Kas dan setara kas berjumlah USD 62 juta per 30 Juni 2026, setelah penawaran umum menghasilkan dana bersih USD 58,3 juta. * Eloxx menargetkan memulai uji klinis Phase 2b exaluren pada kuartal III 2026, menyusul izin melanjutkan dari FDA. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Eloxx Pharmaceuticals Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001193125-26-344964), on August 11, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT) Original Document: here